Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only...

FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – PRVB NEW YORK, July 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...

ROSEN, A TOP RANKED LAW FIRM, Encourages Provention Bio, Inc. Investors With Losses to Secure Counsel Before Important July 20 Deadline in Securities Class Action – PRVB NEW YORK, July 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 20 Deadline – PRVB NEW YORK, May 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...